NEU — Neuren Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$1.40bn
- AU$1.17bn
- AU$224.26m
- 64
- 71
- 25
- 55
Annual income statement for Neuren Pharmaceuticals, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.864 | 3.24 | 15.8 | 238 | 224 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 9.53 | 11.4 | 16.1 | 32.7 | 37.7 |
| Operating Profit | -8.66 | -8.19 | -0.341 | 205 | 187 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.19 | -7.79 | 0.184 | 205 | 183 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.19 | -7.79 | 0.184 | 157 | 142 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.19 | -7.79 | 0.184 | 157 | 142 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.19 | -7.79 | 0.184 | 157 | 142 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.086 | -0.066 | 0.001 | 1.24 | 1.09 |